A developed determination of midazolam and 1′-hydroxymidazolam in plasma by liquid chromatography-mass spectrometry: Application of human pharmacokinetic study for measurement of CYP3A activity

Mikiko Shimizu, Tsukasa Uno, Hiroomi Tamura, Hideko Kanazawa, Isao Murakami, Kazunobu Sugawara, Tomonori Tateishi

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

This paper describes sensitive and reliable determination of midazolam (MDZ) and its major metabolite 1′-hydroxymidazolam (1-OHMDZ) in human plasma by liquid chromatography-mass spectrometry (LC-MS) with a sonic spray ionization (SSI) interface. MDZ, 1-OHMDZ and diazepam as an internal standard were extracted from 1 ml of alkalinized plasma using n-hexane-chloroform (70:30, v/v). The extract was injected into an analytical column (YMC-Pak Pro C18, 50 mm × 2.0 mm i.d.). The mobile phase for separation consisted of 10 mM ammonium acetate and methanol (50:50, v/v) and was delivered at a flow-rate of 0.2 ml/min. The drift voltage was 100 V. The sampling aperture was heated at 120 °C and the shield temperature was 260 °C. The total time for chromatographic separation was less than 16 min. The validated concentration ranges of this method were 0.25-50 ng/ml for both MDZ and 1-OHMDZ. Mean recoveries were 93.6% for MDZ and 86.6% for 1-OHMDZ. Intra- and inter-day coefficient variations were less than 6.5 and 5.5% for MDZ, and 6.1 and 5.7% for 1-OHMDZ at 0.3, 4, 20 and 40 ng/ml. The limits of quantification were 0.25 ng/ml for both MDZ and 1-OHMDZ. This method was sensitive and reliable enough for pharmacokinetic studies on healthy volunteers, and was applied for the measurement of CYP3A activity in humans after an intravenous (1 mg) and a single-oral administration (2 mg) of subtherapeutic MDZ dose.

Original languageEnglish
Pages (from-to)275-281
Number of pages7
JournalJournal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
Volume847
Issue number2
DOIs
Publication statusPublished - 2007 Mar 1

Fingerprint

Cytochrome P-450 CYP3A
Pharmacokinetics
Midazolam
Liquid chromatography
Liquid Chromatography
Mass spectrometry
Mass Spectrometry
Plasmas
Plasma (human)
Diazepam
Chloroform
Metabolites
1-hydroxymethylmidazolam
Human Activities
Ionization
Oral Administration
Methanol
Healthy Volunteers
Flow rate
Sampling

Keywords

  • 1′-Hydroxymidazolam
  • CYP3A
  • LC-MS
  • Midazolam

ASJC Scopus subject areas

  • Biochemistry

Cite this

@article{e6660d33729c4e05b4e98b763b0a80a8,
title = "A developed determination of midazolam and 1′-hydroxymidazolam in plasma by liquid chromatography-mass spectrometry: Application of human pharmacokinetic study for measurement of CYP3A activity",
abstract = "This paper describes sensitive and reliable determination of midazolam (MDZ) and its major metabolite 1′-hydroxymidazolam (1-OHMDZ) in human plasma by liquid chromatography-mass spectrometry (LC-MS) with a sonic spray ionization (SSI) interface. MDZ, 1-OHMDZ and diazepam as an internal standard were extracted from 1 ml of alkalinized plasma using n-hexane-chloroform (70:30, v/v). The extract was injected into an analytical column (YMC-Pak Pro C18, 50 mm × 2.0 mm i.d.). The mobile phase for separation consisted of 10 mM ammonium acetate and methanol (50:50, v/v) and was delivered at a flow-rate of 0.2 ml/min. The drift voltage was 100 V. The sampling aperture was heated at 120 °C and the shield temperature was 260 °C. The total time for chromatographic separation was less than 16 min. The validated concentration ranges of this method were 0.25-50 ng/ml for both MDZ and 1-OHMDZ. Mean recoveries were 93.6{\%} for MDZ and 86.6{\%} for 1-OHMDZ. Intra- and inter-day coefficient variations were less than 6.5 and 5.5{\%} for MDZ, and 6.1 and 5.7{\%} for 1-OHMDZ at 0.3, 4, 20 and 40 ng/ml. The limits of quantification were 0.25 ng/ml for both MDZ and 1-OHMDZ. This method was sensitive and reliable enough for pharmacokinetic studies on healthy volunteers, and was applied for the measurement of CYP3A activity in humans after an intravenous (1 mg) and a single-oral administration (2 mg) of subtherapeutic MDZ dose.",
keywords = "1′-Hydroxymidazolam, CYP3A, LC-MS, Midazolam",
author = "Mikiko Shimizu and Tsukasa Uno and Hiroomi Tamura and Hideko Kanazawa and Isao Murakami and Kazunobu Sugawara and Tomonori Tateishi",
year = "2007",
month = "3",
day = "1",
doi = "10.1016/j.jchromb.2006.10.018",
language = "English",
volume = "847",
pages = "275--281",
journal = "Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences",
issn = "1570-0232",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - A developed determination of midazolam and 1′-hydroxymidazolam in plasma by liquid chromatography-mass spectrometry

T2 - Application of human pharmacokinetic study for measurement of CYP3A activity

AU - Shimizu, Mikiko

AU - Uno, Tsukasa

AU - Tamura, Hiroomi

AU - Kanazawa, Hideko

AU - Murakami, Isao

AU - Sugawara, Kazunobu

AU - Tateishi, Tomonori

PY - 2007/3/1

Y1 - 2007/3/1

N2 - This paper describes sensitive and reliable determination of midazolam (MDZ) and its major metabolite 1′-hydroxymidazolam (1-OHMDZ) in human plasma by liquid chromatography-mass spectrometry (LC-MS) with a sonic spray ionization (SSI) interface. MDZ, 1-OHMDZ and diazepam as an internal standard were extracted from 1 ml of alkalinized plasma using n-hexane-chloroform (70:30, v/v). The extract was injected into an analytical column (YMC-Pak Pro C18, 50 mm × 2.0 mm i.d.). The mobile phase for separation consisted of 10 mM ammonium acetate and methanol (50:50, v/v) and was delivered at a flow-rate of 0.2 ml/min. The drift voltage was 100 V. The sampling aperture was heated at 120 °C and the shield temperature was 260 °C. The total time for chromatographic separation was less than 16 min. The validated concentration ranges of this method were 0.25-50 ng/ml for both MDZ and 1-OHMDZ. Mean recoveries were 93.6% for MDZ and 86.6% for 1-OHMDZ. Intra- and inter-day coefficient variations were less than 6.5 and 5.5% for MDZ, and 6.1 and 5.7% for 1-OHMDZ at 0.3, 4, 20 and 40 ng/ml. The limits of quantification were 0.25 ng/ml for both MDZ and 1-OHMDZ. This method was sensitive and reliable enough for pharmacokinetic studies on healthy volunteers, and was applied for the measurement of CYP3A activity in humans after an intravenous (1 mg) and a single-oral administration (2 mg) of subtherapeutic MDZ dose.

AB - This paper describes sensitive and reliable determination of midazolam (MDZ) and its major metabolite 1′-hydroxymidazolam (1-OHMDZ) in human plasma by liquid chromatography-mass spectrometry (LC-MS) with a sonic spray ionization (SSI) interface. MDZ, 1-OHMDZ and diazepam as an internal standard were extracted from 1 ml of alkalinized plasma using n-hexane-chloroform (70:30, v/v). The extract was injected into an analytical column (YMC-Pak Pro C18, 50 mm × 2.0 mm i.d.). The mobile phase for separation consisted of 10 mM ammonium acetate and methanol (50:50, v/v) and was delivered at a flow-rate of 0.2 ml/min. The drift voltage was 100 V. The sampling aperture was heated at 120 °C and the shield temperature was 260 °C. The total time for chromatographic separation was less than 16 min. The validated concentration ranges of this method were 0.25-50 ng/ml for both MDZ and 1-OHMDZ. Mean recoveries were 93.6% for MDZ and 86.6% for 1-OHMDZ. Intra- and inter-day coefficient variations were less than 6.5 and 5.5% for MDZ, and 6.1 and 5.7% for 1-OHMDZ at 0.3, 4, 20 and 40 ng/ml. The limits of quantification were 0.25 ng/ml for both MDZ and 1-OHMDZ. This method was sensitive and reliable enough for pharmacokinetic studies on healthy volunteers, and was applied for the measurement of CYP3A activity in humans after an intravenous (1 mg) and a single-oral administration (2 mg) of subtherapeutic MDZ dose.

KW - 1′-Hydroxymidazolam

KW - CYP3A

KW - LC-MS

KW - Midazolam

UR - http://www.scopus.com/inward/record.url?scp=33847331529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847331529&partnerID=8YFLogxK

U2 - 10.1016/j.jchromb.2006.10.018

DO - 10.1016/j.jchromb.2006.10.018

M3 - Article

C2 - 17085083

AN - SCOPUS:33847331529

VL - 847

SP - 275

EP - 281

JO - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

JF - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

SN - 1570-0232

IS - 2

ER -